Reference Summary: Kevin Kalinsky, MD, MS, Emory University Hospital, Atlanta, GA, discusses the results of a study looking at real-world sacituzumab ... In this clip from Breast Cancer Breakthroughs, you'll learn how the PI3K Pathway contributes to breast cancer, and Komen Scholar ...

Zetagen Overview 35783 -

Kevin Kalinsky, MD, MS, Emory University Hospital, Atlanta, GA, discusses the results of a study looking at real-world sacituzumab ... In this clip from Breast Cancer Breakthroughs, you'll learn how the PI3K Pathway contributes to breast cancer, and Komen Scholar ... The p53 gene is mutated in over 50% of all cancers and without it, not only can cancer cells spread, but they can also become ...

Important details found

  • Kevin Kalinsky, MD, MS, Emory University Hospital, Atlanta, GA, discusses the results of a study looking at real-world sacituzumab ...
  • In this clip from Breast Cancer Breakthroughs, you'll learn how the PI3K Pathway contributes to breast cancer, and Komen Scholar ...
  • The p53 gene is mutated in over 50% of all cancers and without it, not only can cancer cells spread, but they can also become ...
  • Discover the breakthrough clinical trial results from the 2025 San Antonio Breast Cancer Symposium that are set to redefine ...
  • Gerald Steven Falchook, MD, Sarah Cannon Research Institute at HealthONE, Denver, CO, provides an

Why this topic is useful

A structured page helps reduce disconnected snippets by grouping the main subject with context, examples, and nearby entries.

Sponsored

Frequently Asked Questions

Is the information always complete?

Not always. Some topics may need verification from official or primary sources.

How should readers use this information?

Use it as a starting point, then open related pages for more specific details.

What should readers check next?

Readers should check related pages, official references, or updated sources when details matter.

Image References

Breast Cancer Breakthroughs: Overview of the PI3K Pathway in Breast Cancer and Drugs that Target It
A cancer breakthrough: p53 and Gendicine
3 Breast Cancer Trials That Will Change Care in 2026
Dr. Matthew Goetz discusses Z-endoxifen
Study of sacituzumab govitecan for triple-negative breast cancer
Real-word efficacy of sacituzumab govitecan in metastatic triple-negative breast cancer
ASCENT-05: sacituzumab govitecan and pembrolizumab in TNBC
Theranostics - Where personalized cancer care starts
GenomeConnect Webinar - Precision Therapeautics
B7-H6/CD3 T-cell engager BI 765049 ± ezabenlimab in advanced solid tumors expressing B7-H6
Sponsored
View Full Details
Breast Cancer Breakthroughs: Overview of the PI3K Pathway in Breast Cancer and Drugs that Target It

Breast Cancer Breakthroughs: Overview of the PI3K Pathway in Breast Cancer and Drugs that Target It

In this clip from Breast Cancer Breakthroughs, you'll learn how the PI3K Pathway contributes to breast cancer, and Komen Scholar ...

A cancer breakthrough: p53 and Gendicine

A cancer breakthrough: p53 and Gendicine

The p53 gene is mutated in over 50% of all cancers and without it, not only can cancer cells spread, but they can also become ...

3 Breast Cancer Trials That Will Change Care in 2026

3 Breast Cancer Trials That Will Change Care in 2026

Discover the breakthrough clinical trial results from the 2025 San Antonio Breast Cancer Symposium that are set to redefine ...

Dr. Matthew Goetz discusses Z-endoxifen

Dr. Matthew Goetz discusses Z-endoxifen

Read more details and related context about Dr. Matthew Goetz discusses Z-endoxifen.

Study of sacituzumab govitecan for triple-negative breast cancer

Study of sacituzumab govitecan for triple-negative breast cancer

Read more details and related context about Study of sacituzumab govitecan for triple-negative breast cancer.

Real-word efficacy of sacituzumab govitecan in metastatic triple-negative breast cancer

Real-word efficacy of sacituzumab govitecan in metastatic triple-negative breast cancer

Kevin Kalinsky, MD, MS, Emory University Hospital, Atlanta, GA, discusses the results of a study looking at real-world sacituzumab ...

ASCENT-05: sacituzumab govitecan and pembrolizumab in TNBC

ASCENT-05: sacituzumab govitecan and pembrolizumab in TNBC

Sara Tolaney, MD, MPH, Dana-Farber Cancer Institute, Boston, MA, provides an

Theranostics - Where personalized cancer care starts

Theranostics - Where personalized cancer care starts

Cancer is personal. Its treatment should be too. GE Healthcare's complete portfolio of Theranostics-enabling solutions is designed ...

GenomeConnect Webinar - Precision Therapeautics

GenomeConnect Webinar - Precision Therapeautics

In this recorded webinar, Rebecca Smith from The Jackson Laboratory, provides an

B7-H6/CD3 T-cell engager BI 765049 ± ezabenlimab in advanced solid tumors expressing B7-H6

B7-H6/CD3 T-cell engager BI 765049 ± ezabenlimab in advanced solid tumors expressing B7-H6

Gerald Steven Falchook, MD, Sarah Cannon Research Institute at HealthONE, Denver, CO, provides an